Analysts have suggested that having a second NK-acting drug in the marketplace could raise awareness and help drive the uptake of both products, which are expected to appeal to women unwilling to ...

Amgen reported sales of $272 million for the drug after it took ownership in 2023 and $235 million in the first quarter of this year. Sobi licensed SEL-212 from Selecta Biosciences – now called ...